Success Metrics

Clinical Success Rate
66.7%

Based on 2 completed trials

Completion Rate
67%(2/3)
Active Trials
0(0%)
Results Posted
100%(2 trials)
Terminated
1(20%)

Phase Distribution

Ph not_applicable
4
80%
Ph phase_1
1
20%

Phase Distribution

1

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
1(20.0%)
N/ANon-phased studies
4(80.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

66.7%

2 of 3 finished

Non-Completion Rate

33.3%

1 ended early

Currently Active

0

trials recruiting

Total Trials

5

all time

Status Distribution
Completed(2)
Terminated(1)
Other(2)

Detailed Status

Completed2
unknown2
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
0
Success Rate
66.7%
Most Advanced
Phase 1

Trials by Phase

Phase 11 (20.0%)
N/A4 (80.0%)

Trials by Status

terminated120%
completed240%
unknown240%

Recent Activity

0 active trials
Showing 5 of 5
completednot_applicable

Response Inhibition in Tourette Syndrome

NCT03628703
terminatednot_applicable

Effects of rTMS on Human Brain Activity Measured With fMRI

NCT03259568
unknownnot_applicable

rTMS and Robotic Gait Training in Patients With Stroke

NCT03817385
completednot_applicable

A Study of rTMS for Cognitive Deficits in Chronic Patients With Schizophrenia

NCT03273439
unknownphase_1

rTMS for Adults With Autistic Spectrum Disorder

NCT01918787

Clinical Trials (5)

Showing 5 of 5 trials
NCT03628703Not Applicable

Response Inhibition in Tourette Syndrome

Completed
NCT03259568Not Applicable

Effects of rTMS on Human Brain Activity Measured With fMRI

Terminated
NCT03817385Not Applicable

rTMS and Robotic Gait Training in Patients With Stroke

Unknown
NCT03273439Not Applicable

A Study of rTMS for Cognitive Deficits in Chronic Patients With Schizophrenia

Completed
NCT01918787Phase 1

rTMS for Adults With Autistic Spectrum Disorder

Unknown

All 5 trials loaded

Drug Details

Intervention Type
DEVICE
Total Trials
5